miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A-Reference-Cited by-同舟云学术

miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A

Published:2019-06-21 Issue:1 Volume:38 Page:
ISSN:1756-9966
Container-title:Journal of Experimental & Clinical Cancer Research
language:en
Short-container-title:J Exp Clin Cancer Res

Author:

Caporali Simona,Amaro Adriana,Levati Lauretta,Alvino Ester,Lacal Pedro Miguel,Mastroeni Simona,Ruffini Federica,Bonmassar Laura,Antonini Cappellini Gian Carlo,Felli Nadia,Carè Alessandra,Pfeffer Ulrich,D’Atri Stefania

Funder

Associazione Italiana per la Ricerca sul Cancro

Ministero della Salute

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1186/s13046-019-1238-4.pdf

Reference73 articles.

1. Schadendorf D, Fisher DE, Garbe C, Gershenwald JE, Grob J-J, Halpern A, et al. Melanoma. Nat Rev Dis Prim. 2015;1:15003.

2. Balch CM, Gershenwald JE, Soong S-J, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199–206.

3. Shirley M. Encorafenib and Binimetinib: First Global Approvals. Drugs. 2018;78:1277–84.

4. Ugurel S, Röhmel J, Ascierto PA, Flaherty KT, Grob JJ, Hauschild A, et al. Survival of patients with advanced metastatic melanoma: the impact of novel therapies–update 2017. Eur J Cancer. 2017;83:247–57.

5. Amaral T, Sinnberg T, Meier F, Krepler C, Levesque M, Niessner H, et al. The mitogen-activated protein kinase pathway in melanoma part I – Activation and primary resistance mechanisms to BRAF inhibition. Eur J Cancer. 2017;73:85–92.

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Determinants of resistance and response to melanoma therapy;Nature Cancer;2024-07-17

2. VEGF/VEGFR axis and its signaling in melanoma: Current knowledge toward therapeutic targeting agents and future perspectives;Life Sciences;2024-05

3. MicroRNAs and proteolytic cleavage of receptors in cancers: A comprehensive review of regulatory interactions and therapeutic implications;Heliyon;2024-04

4. Exploring the oncogenic and tumor-suppressive roles of Circ-ADAM9 in cancer;Pathology - Research and Practice;2024-04

5. Role and Function of Receptor Tyrosine Kinases in BRAF Mutant Cancers;Receptors;2024-03-04